Imaging AI in Texas

Synthesis Health Intelligence Inc. develops an intelligent, cloud-native radiology platform designed to enhance workflow efficiency and reporting accuracy for hospitals, imaging centers, and teleradiology groups. The company addresses the critical radiologist shortage through comprehensive software solutions that integrate PACS replacement, reporting, speech recognition, AI integration, and image management. The Synthesis platform includes a diagnostic and enterprise image viewer (Synthesis VISION, FDA 510(k) cleared), unified worklist management, automated exam assignment, DICOM-compliant cloud archive, and advanced clinical reporting with SynthSpeech cloud-based speech recognition. The platform incorporates the proprietary Synthesis Playbook—standardized modalities, exam types, body regions, report templates, and hanging protocols—enabling seamless deployment across multiple institutions. Key capabilities include AI-based auto-impression and report corrections, breast imaging workflows, structured reporting interoperability, intelligent data normalization, and multi-tenant architecture for healthcare networks. The company integrates FDA-cleared third-party AI applications and provides built-in training, peer review, critical results tracking, and messaging. Infrastructure complies with HIPAA and PIPEDA, with platform security certified to HITRUST, SOC2, and ISO 27001 standards. Synthesis markets to imaging healthcare professionals (radiologists, technologists, administrators) and OEMs seeking cloud migration, legacy PACS overlay or replacement, and cost-effective AI deployment at scale.

Perimeter Medical Imaging AI is a medical technology company specializing in intraoperative optical coherence tomography (OCT) imaging systems enhanced with artificial intelligence for cancer surgery guidance. The company's FDA-cleared Perimeter S-Series OCT and next-generation B-Series OCT with ImgAssist AI software provide real-time, cellular-level margin visualization during breast-conserving surgery and other oncologic procedures. These systems enable surgeons to identify residual tumor tissue and assess surgical margins with unprecedented clarity, reducing re-excision rates and repeat surgeries. Perimeter's technology leverages advanced optical imaging and machine learning algorithms to deliver actionable intraoperative insights, helping surgical teams close with confidence while improving patient outcomes and lowering healthcare costs. The company operates from Dallas, Texas with headquarters in Toronto, Canada.

Spectral MD (trading as Spectral AI) is a Dallas-based medical device company specializing in predictive wound healing diagnostics. The company's flagship product, the DeepView® Wound Imaging System, combines multispectral imaging technology with proprietary artificial intelligence algorithms to provide rapid, noninvasive wound healing assessments. The system differentiates between damaged and healthy tissue, delivering immediate binary healing predictions and detailed healing maps on Day One of assessment. DeepView supports clinical decision-making across multiple wound types including burns, diabetic foot ulcers, and acute/chronic wounds. The technology has received FDA Breakthrough Device Designation. The company is publicly traded on NASDAQ (ticker: MDAI) and holds 12 U.S. patents and 14 foreign patents related to its multispectral imaging and predictive AI platform.

Biokinemetrics is a healthcare technology company delivering hospital-grade digital X-ray imaging systems, software platforms, and teleradiology services to independent medical practices, urgent care facilities, chiropractors, and veterinary clinics. The company specializes in space-efficient diagnostic imaging solutions designed for small-to-medium practices, offering integrated hardware and software packages that streamline clinical workflows, reduce operational complexity, and enhance diagnostic accuracy. Core offerings include ChiroSight (chiropractic imaging), VetSight (veterinary imaging), MedSight (medical practice imaging), and TeleRad (remote radiology consultation services). Biokinemetrics focuses on delivering equipment integration, comprehensive reporting tools, medical imaging system upgrades, warranty support, and tele-radiology services that enable practitioners to diagnose faster, manage operations more efficiently, and improve patient outcomes without requiring enterprise-scale infrastructure.

MedCognetics, Inc. is a healthcare AI company specializing in breast cancer detection and diagnostic assistance. The company develops AI-powered solutions designed to augment radiologist workflows in mammography screening, with a focus on improving early breast cancer detection and reducing radiologist burnout. MedCognetics' primary product, CogNet AI-MT+, received FDA clearance and is designed to triage mammography cases by flagging suspicious findings, enabling radiologists to prioritize high-risk cases and improve diagnostic efficiency. The platform addresses critical clinical needs including radiologist shortages, heavy workloads, and prolonged work hours in breast imaging departments. MedCognetics emphasizes development of unbiased AI algorithms through sourcing diverse patient datasets globally, reflecting a commitment to equitable performance across diverse populations. The company partners with leading academic and medical institutions including UT Dallas, UT Southwestern Medical Center, and specialized radiology organizations, supporting clinical validation and deployment. The solution is positioned for use in resource-constrained regions where radiologist availability cannot meet screening demand, as well as in established healthcare systems seeking to enhance diagnostic accuracy and operational efficiency.

Medical Metrics, Inc. (MMI) is an independent, full-service imaging core laboratory and clinical consulting firm specializing in centralized image analysis, endpoint strategy design, and regulatory support for clinical trials and medical device development. Founded 21+ years ago, MMI serves over 260 clients and partners globally, having supported 695+ clinical trials and contributed to more than 50 FDA regulatory approvals and clearances. The company operates a science-first approach with a multidisciplinary team of biomedical engineers, medical imaging specialists, and physician reviewers who design customized imaging methodologies and protocols for device sponsors, biopharmaceutical companies, and contract research organizations. Core services include imaging endpoint strategy and scientific consulting, image review charter development, clinical site management and training, image quality and compliance monitoring, expert centralized image analysis (via independent physician readers), data interpretation, publication strategy, and post-market surveillance. MMI maintains expertise across multiple therapeutic areas including spine (fusion, motion preservation, deformity correction), orthopedics (joint arthroplasty, biologics, cartilage repair), cardiovascular (peripheral vascular disease, atherectomy, stents), neurology (stroke, aneurysm, tumor), ENT, gastrointestinal and urology, oncology, and artificial intelligence research. The firm is ISO 13485 certified and operates with emphasis on accuracy, reliability, independence, and integrity in imaging outcomes assessment.